Cargando…

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England

In England, during pandemic 2009 H1N1, vaccine efficacy and immunogenicity population studies in priority groups were rolled out in parallel to evaluate the pandemic vaccination programme. This provided a unique opportunity to compare immunogenicity and clinical protection in the same population and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yung, Chee-Fu, Andrews, Nick, Hoschler, Katja, Miller, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579930/ https://www.ncbi.nlm.nih.gov/pubmed/23451097 http://dx.doi.org/10.1371/journal.pone.0056844

Ejemplares similares

Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England
por: Andrews, Nick, et al.
Publicado: (2011)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

Age-Specific Incidence of A/H1N1 2009 Influenza Infection in England from Sequential Antibody Prevalence Data Using Likelihood-Based Estimation
por: Baguelin, Marc, et al.
Publicado: (2011)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study
por: Stowe, Julia, et al.
Publicado: (2020)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011
por: Hoschler, Katja, et al.
Publicado: (2012)

Seroepidemiologic Study of Pandemic (H1N1) 2009 during Outbreak in Boarding School, England
por: Johnson, Sandra, et al.
Publicado: (2011)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
por: Cohet, Catherine, et al.
Publicado: (2016)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

PHASE 3 STUDY OF SAFETY AND IMMUNOGENICITY OF GBP510 VACCINE ADJUVANTED WITH AS03 IN ADULTS
por: Song, J.Y., et al.
Publicado: (2023)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
por: Walker, Woolf T., et al.
Publicado: (2012)

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016)

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010
por: Calatayud, Laurence, et al.
Publicado: (2011)

Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
por: Hoschler, Katja, et al.
Publicado: (2020)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

Mortality Attributable to Influenza in England and Wales Prior to, during and after the 2009 Pandemic
por: Green, Helen K., et al.
Publicado: (2013)

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial
por: Scheifele, David W., et al.
Publicado: (2013)

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
por: Charland, Nathalie, et al.
Publicado: (2022)

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

Incidence of Influenza A(H1N1)pdm09 Infection, United Kingdom, 2009–2011
por: Sridhar, Saranya, et al.
Publicado: (2013)

Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients
por: Miraglia, João L., et al.
Publicado: (2011)

Mumps Complications and Effects of Mumps Vaccination, England and Wales, 2002–2006
por: Yung, Chee-Fu, et al.
Publicado: (2011)

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains
por: Höschler, Katja, et al.
Publicado: (2008)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

Has estimation of numbers of cases of pandemic influenza H1N1 in England in 2009 provided a useful measure of the occurrence of disease?
por: Evans, Barry, et al.
Publicado: (2011)

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
por: Launay, Odile, et al.
Publicado: (2013)

Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study
por: Choi, Yoon Hong, et al.
Publicado: (2019)

Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009
por: Ladhani, Shamez N., et al.
Publicado: (2012)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Cortaillod 21.1.03 Techmeta 26.03.03 CMS SUPRA
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_7pm5khhb270jqno9gj2ha0bgo8